InvestorsHub Logo
Followers 58
Posts 10107
Boards Moderated 1
Alias Born 09/21/2016

Re: Talon38 post# 119947

Wednesday, 09/13/2017 8:36:09 AM

Wednesday, September 13, 2017 8:36:09 AM

Post# of 460518

Gottlieb and Woodcock have everything to gain by guiding ANAVEX 2-73 to success as the SOC for Alzheimer's....inexpensive restoration of the 5 to 10 million current sufferers and a possible preventative solution to a rapidly aging population. Think we will see a very tailored and efficient upcoming P3 with a more than likely US arm.



Agree with this observation. Would add that for this and other reasons they must now be involved up to HERE. Analysis of pre trial data, planning "what if's", including ..."what if it works...then what?".
No way a company the size of an SUV will be capable of dealing with millions of deserving patients, WW. I would like to think that the FDA has someone thinking about the consequences of approvals, b/c no way AVXL can handle that alone.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News